The board of directors of Kintor Pharmaceutical Limited announced that on 14 April 2023, the Company has completed the first subject enrollment in the phase II clinical trial in China of its proteolysis targeting chimera (PROTAC) compound GT20029 for the treatment of male androgenetic alopecia (AGA). GT20029 was developed based on the in-house PROTAC platform of the Company and is the first topical PROTAC compound which has entered the phase II clinical stage worldwide. The Phase II Clinical Trial is a multi-center, randomized, double-blind, placebo-controlled study, which was designed to evaluate the efficacy and safety of GT20029 for treating male AGA adults and determine the recommended dosage for phase III clinical trial in China.

The primary endpoint of this trial is the change from baseline in non-vellus target area hair counts (TAHC) after 12 weeks of treatment in comparison to placebo. It plans to enroll a total of 180 subjects from 12 centers nationwide. In November 2022 and February 2023, the Company respectively announced the positive top-line data for the phase I clinical trial of GT200 29 for the treatment of AGA and acne in China (healthy subjects) and in the U.S. (healthy subjects and subjects with AGA or acne).

The data demonstrated good safety, tolerability and pharmacokinetics of GT20029 in healthy subjects or subjects with AGA or acne.